2.44
3.39%
+0.08
After Hours:
2.44
Standard BioTools Inc stock is currently priced at $2.44, with a 24-hour trading volume of 3.64M.
It has seen a +3.39% increased in the last 24 hours and a -7.58% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.31 pivot point. If it approaches the $2.45 resistance level, significant changes may occur.
Previous Close:
$2.36
Open:
$2.35
24h Volume:
3.64M
Market Cap:
$933.21M
Revenue:
$106.34M
Net Income/Loss:
$-74.66M
P/E Ratio:
-2.3019
EPS:
-1.06
Net Cash Flow:
$-46.12M
1W Performance:
-3.17%
1M Performance:
-7.58%
6M Performance:
+23.23%
1Y Performance:
+47.88%
Standard BioTools Inc Stock (LAB) Company Profile
Name
Standard BioTools Inc
Sector
Industry
Phone
650 266 6000
Address
2 Tower Place, Suite 2000, South San Francisco
Standard BioTools Inc Stock (LAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard BioTools Inc Stock (LAB) Latest News
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
GlobeNewswire Inc.
Labrador Gold Announces Sale of Kingsway Project
GlobeNewswire Inc.
Labrador Gold Files NI43-101 Technical Report for the Kingsway Project
GlobeNewswire Inc.
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
GlobeNewswire Inc.
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
GlobeNewswire Inc.
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
GlobeNewswire Inc.
Standard BioTools Inc Stock (LAB) Financials Data
Standard BioTools Inc (LAB) Revenue 2024
LAB reported a revenue (TTM) of $106.34 million for the quarter ending December 31, 2023, a +8.57% rise year-over-year.
Standard BioTools Inc (LAB) Net Income 2024
LAB net income (TTM) was -$74.66 million for the quarter ending December 31, 2023, a +60.73% increase year-over-year.
Standard BioTools Inc (LAB) Cash Flow 2024
LAB recorded a free cash flow (TTM) of -$46.12 million for the quarter ending December 31, 2023, a +50.51% increase year-over-year.
Standard BioTools Inc (LAB) Earnings per Share 2024
LAB earnings per share (TTM) was -$0.95 for the quarter ending December 31, 2023, a +61.07% growth year-over-year.
About Standard BioTools Inc
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):